利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.04 秒)

    Melanocortin receptor ligands
    4.
    发明授权
    Melanocortin receptor ligands 失效
    黑皮质素受体配体

    公开(公告)号：US06613874B1

    公开(公告)日：2003-09-02

    申请号：US09537789

    申请日：2000-03-29

    申请人： Adam Wieslaw Mazur ,  Feng Wang ,  Russell James Sheldon ,  Frank Hallock Ebetino

    发明人： Adam Wieslaw Mazur ,  Feng Wang ,  Russell James Sheldon ,  Frank Hallock Ebetino

    IPC分类号： C07K750

    CPC分类号： C07K14/685 ,  A61K38/00 ,  C07K14/68

    摘要： Disclosed are cyclic peptide analogs that are MC-4 and/or MC-3 receptor ligands, the analogs having a structure according to Formula (I): wherein B, X, E, Z, D, G, M′, W, R, R1, R1′, R11, m, n, p and q are as described in the specification. The peptide analogs are useful in treating diseases that are mediated by the MC-4 and/or the MC-3 receptor. As such, the invention is directed to methods of treating body weight disorders, such as obesity, anorexia, and cachexia. The invention also relates to the treatment of CNS depression, behavior-related disorders, memory-related disorders, cardiovascular function, inflammation, sepsis, septic shock, cardiogenic shock, hypovolemic shock, sexual dysfunction, erectile dysfunction, muscle atrophy, diseases associated with nerve growth and repair, and intrauterine fetal growth. Also disclosed are pharmaceutical compositions comprising the peptide analogs of Formula (I).

    摘要翻译： 公开了作为MC-4和/或MC-3受体配体的环肽类似物，该类似物具有式（I）的结构：其中B，X，E，Z，D，G，M'，W，R ，R1，R1'，R11，m，n，p和q如说明书中所述。 肽类似物可用于治疗由MC-4和/或MC-3受体介导的疾病。 因此，本发明涉及治疗体重障碍，例如肥胖症，厌食症和恶病质的方法。 本发明还涉及CNS抑郁症，行为相关障碍，记忆相关障碍，心血管功能，炎症，败血症，败血症休克，心源性休克，血容量不足休克，性功能障碍，勃起功能障碍，肌肉萎缩，与神经相关的疾病 生长和修复，宫内胎儿生长。 还公开了包含式（I）的肽类似物的药物组合物。

    Composition for treating bone disorders
    5.
    发明授权
    Composition for treating bone disorders 有权
    用于治疗骨骼疾病的组合物

    公开(公告)号：US07781418B2

    公开(公告)日：2010-08-24

    申请号：US12001318

    申请日：2007-12-11

    申请人： Frank Hallock Ebetino ,  Robert Kenneth Boeckman, Jr. ,  Xinyi Song

    发明人： Frank Hallock Ebetino ,  Robert Kenneth Boeckman, Jr. ,  Xinyi Song

    IPC分类号： A61K31/675 ,  A61K31/44 ,  A01N43/42

    CPC分类号： C07F9/5765

    摘要： Disclosed is a new composition of matter, substantially enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid, methods of preparing this new composition of matter, a pharmaceutical composition comprising the new composition, and administration of the composition in methods of treating bone disorders such as osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis.

    摘要翻译： 公开了一种新的物质组合物，基本上为对映异构体纯的（1R，6S）-2-氮杂双环[4.3.0]壬烷-8,8-二膦酸，制备这种新的物质组合物的方法，包含新的 组合物和组合物在治疗骨质疏松症，溶骨性骨转移，类风湿性关节炎和骨关节炎等骨病的方法中的用途。

    2-decarboxy-2-phosphinico Prostaglandin F analogs
    6.
    发明授权
    2-decarboxy-2-phosphinico Prostaglandin F analogs 有权
    2-decarboxy-2-phosphinico前列腺素F类似物

    公开(公告)号：US06372730B1

    公开(公告)日：2002-04-16

    申请号：US09632256

    申请日：2000-08-03

    申请人： Mitchell Anthony deLong ,  John August Wos ,  Biswanath De ,  Frank Hallock Ebetino

    发明人： Mitchell Anthony deLong ,  John August Wos ,  Biswanath De ,  Frank Hallock Ebetino

    IPC分类号： A61K3166

    CPC分类号： C07F9/303

    摘要： The invention provides novel Prostaglandin F analogs. In particular, the present invention is directed to compounds having a structure according to the following formula: wherein R1, R2, X, Y, V, a, b, W, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically—acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

    摘要翻译： 本发明提供了新型前列腺素F类似物。 特别地，本发明涉及具有下式结构的化合物：其中R1，R2，X，Y，V，a，b，W和Z定义如下。本发明还包括光学异构体，非对映异构体 和上式的对映异构体及其药学上可接受的盐，生物可水解的酰胺，酯和酰亚胺。本发明的化合物可用于治疗多种疾病和病症，例如骨骼疾病和青光眼。 因此，本发明还提供包含这些化合物的药物组合物。 本发明还提供了使用这些化合物或含有它们的组合物治疗骨病和青光眼的方法。

    Melanocortin receptor ligands
    8.
    发明授权
    Melanocortin receptor ligands 失效
    黑皮质素受体配体

    公开(公告)号：US07026335B2

    公开(公告)日：2006-04-11

    申请号：US10410775

    申请日：2003-04-09

    申请人： Frank Hallock Ebetino ,  Xuewei Liu ,  Mark Gregory Solinsky ,  John August Wos

    发明人： Frank Hallock Ebetino ,  Xuewei Liu ,  Mark Gregory Solinsky ,  John August Wos

    IPC分类号： A61K31/445 ,  C07D401/04

    CPC分类号： C07D401/06 ,  C07D211/26

    摘要： The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein preferably R is substituted aryl, W is a pendant unit having the formula: -L-Q L is a linking unit, Q is preferably a cyclic hydrocarbyl unit; W1 is preferably a carbocyclic unit and W2 is a heteroatom comprising unit.

    摘要翻译： 本发明涉及包含与取代或未取代的烃基环连接的4-取代的哌啶环的化合物。 化合物，包括所有对映异构体和非对映体形式及其药学上可接受的盐，具有下式：其中优选R是取代的芳基，W是具有下式的侧链单元：<？in-line-formula description =“In-line Formulas” - =“lead”？> - LQ <？in-line-formula description =“In-line Formulas”end =“tail”？> L是连接单元，Q优选为环状烃基单元; W 1优选是碳环单元，W 2是含杂原子的单元。